S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
The ONLY Way to Play Markets Like These (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
The ONLY Way to Play Markets Like These (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
The ONLY Way to Play Markets Like These (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
The ONLY Way to Play Markets Like These (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
The ONLY Way to Play Markets Like These (Ad)pixel
NASDAQ:CTMX

CytomX Therapeutics - CTMX Stock Forecast, Price & News

$1.73
+0.06 (+3.59%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.67
$1.76
50-Day Range
$1.23
$1.97
52-Week Range
$1.19
$7.53
Volume
1.29 million shs
Average Volume
1.26 million shs
Market Capitalization
$114.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.89

CytomX Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
182.6% Upside
$4.89 Price Target
Short Interest
Healthy
2.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.56
Upright™ Environmental Score
News Sentiment
0.69mentions of CytomX Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$51,306 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.16) to ($0.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

139th out of 1,125 stocks

Pharmaceutical Preparations Industry

56th out of 554 stocks

CTMX stock logo

About CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics Stock Up 3.6 %

CTMX Stock opened at $1.73 on Tuesday. The company has a fifty day moving average price of $1.63 and a 200-day moving average price of $2.42. CytomX Therapeutics has a 52-week low of $1.19 and a 52-week high of $7.53.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CTMX. StockNews.com raised shares of CytomX Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, August 5th. BMO Capital Markets dropped their target price on shares of CytomX Therapeutics from $9.00 to $3.00 and set a "buy" rating on the stock in a report on Thursday, July 7th. HC Wainwright cut shares of CytomX Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, July 11th. Mizuho cut shares of CytomX Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the company from $16.00 to $4.00 in a report on Thursday, July 7th. Finally, BTIG Research decreased their price target on shares of CytomX Therapeutics from $16.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, July 7th. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $4.89.

Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

CytomX Therapeutics (NASDAQ:CTMX) Upgraded at StockNews.com
CytomX Therapeutics Provides Strategic Update
Analyst Ratings for CytomX Therapeutics
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Company Calendar

Last Earnings
11/04/2021
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.89
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+182.6%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

Net Income
$-83,610,000.00
Net Margins
-133.42%
Pretax Margin
-133.42%

Debt

Sales & Book Value

Annual Sales
$69.57 million
Book Value
$1.37 per share

Miscellaneous

Free Float
61,663,000
Market Cap
$114.09 million
Optionable
Optionable
Beta
0.49

Key Executives

  • Dr. Sean A. McCarthy D.Phil. (Age 55)
    DPHIL, Chairman & CEO
    Comp: $980.33k
  • Dr. Amy C. Peterson M.D. (Age 55)
    Pres & COO
    Comp: $792.41k
  • Mr. Carlos Campoy (Age 57)
    Sr. VP & CFO (Leave of Absence)
    Comp: $678.35k
  • Mr. Lloyd A. Rowland Jr. (Age 65)
    J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $594.07k
  • Dr. Alison L. Hannah M.D. (Age 61)
    Sr. VP & Chief Medical Officer
    Comp: $659.8k
  • Mr. Christopher W. Ogden (Age 38)
    Interim Principal Accounting Officer and VP of Fin. & Accounting
  • Dr. Chau Cheng M.B.A.
    Ph.D., VP of Investor Relations & Corp. Communications
  • Ms. Danielle Olander
    Sr. VP, Talent & Systems Devel.
  • Ms. Leslie Robbins
    Sr. VP of Intellectual Property
  • Dr. Marcia P. Belvin Ph.D.
    Sr. VP & Head of Research













CTMX Stock - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price forecast for 2022?

11 brokers have issued 1 year price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $11.00. On average, they anticipate the company's share price to reach $4.89 in the next twelve months. This suggests a possible upside of 182.6% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2022?

CytomX Therapeutics' stock was trading at $4.33 at the beginning of 2022. Since then, CTMX stock has decreased by 60.0% and is now trading at $1.73.
View the best growth stocks for 2022 here
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.05. The biotechnology company had revenue of $17.59 million for the quarter, compared to analyst estimates of $18.53 million. CytomX Therapeutics had a negative net margin of 133.42% and a negative trailing twelve-month return on equity of 121.88%. During the same period in the previous year, the company earned ($0.32) EPS.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (4.17%), Renaissance Technologies LLC (2.21%), Millennium Management LLC (2.19%), Laurion Capital Management LP (1.93%), Platinum Investment Management Ltd. (1.86%) and Pictet Asset Management SA (1.00%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.73.

How much money does CytomX Therapeutics make?

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $114.09 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

The company employs 174 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.

This page (NASDAQ:CTMX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.